Physician profile
Omar Taleb
NPI 1912639899
$295.16
in general payments reported to CMS, 2019-2025
12 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $23.74 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $295.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $63.57 | 2025 | Octagam Immune Globulin (Human) |
| Tersera Therapeutics LLC | $34.71 | 2025 | Xermelo |
| Genentech USA, INC. | $27.66 | 2025 | Itovebi |
| Ucb, INC. | $23.74 | 2024 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $23.46 | 2025 | |
| Sobi, INC | $21.29 | 2025 | |
| Abbvie INC. | $18.59 | 2025 | |
| Abbott Laboratories | $18.48 | 2025 | Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.77 | 2025 | Jardiance |
| Edwards Lifesciences Corporation | $16.71 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Stemline Therapeutics INC. | $15.41 | 2025 | Elzonris |
| Deciphera Pharmaceuticals INC. | $14.77 | 2025 | Romvimza, Qinlock |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Taleb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.